Erdosteine has been positively tested as Long COVID-19 treatment
Recipharm is pleased to announce that the results of a new study with erdosteine in "Long COVID-19" treatment are now available.
The study involved 38 COVID-19 post-discharged patients, divided into two groups: one taking erdosteine and one as control arm.
The study demonstrates that patients taking erdosteine 300 mg twice daily experience a significant greater improvement in respiratory symptoms and quality of life, compared to control arm. These outcomes confirm that erdosteine can be an effective treatment against persistent COVID-19 symptoms and can avoid the complications of Long COVID-19. Click here to access the new publication.
